Humulin 30/70 (Miscela) (Insulin Human)

Humulin 30/70 is indicated for the glycemic control of patients with diabetes mellitus when a mixed insulin formulation is appropriate.

• Type 1 diabetes mellitus requiring both basal and prandial insulin coverage.
• Type 2 diabetes mellitus inadequately controlled with oral agents alone.
• Adults and pediatric patients who prefer fewer daily injections compared with separate basal and rapid‑acting insulins.
• Situations where a predictable 30/70 ratio simplifies dose titration.
• Use in combination with diet, exercise, and other antidiabetic medications as part of a comprehensive management plan.

• Humulin 30/70 delivers two insulin components that act on the same insulin receptor. The soluble fraction begins to bind receptors within 30 minutes, promoting rapid glucose uptake in muscle and adipose tissue and suppressing hepatic glucose output. The NPH fraction releases more slowly, maintaining receptor activation for up to 24 hours and providing basal insulin coverage. Together they lower circulating blood glucose by enhancing peripheral utilization and reducing hepatic production.

Adverse reactions to Humulin 30/70 may vary in frequency and severity.

Common

• Mild hypoglycemia, especially if meals are missed or delayed.
• Injection‑site redness, swelling, or itching.
• Lipodystrophy presenting as localized thickening or thinning of subcutaneous tissue.
• Transient weight gain due to fluid retention.

Serious

• Severe hypoglycemia with neuroglycopenic symptoms (confusion, seizures, loss of consciousness).
• Allergic reactions such as urticaria, angioedema, or anaphylaxis.
• Persistent or worsening edema and heart failure exacerbation.

Clinicians should consider several precautions when prescribing Humulin 30/70 to ensure safe and effective use.

• Assess renal and hepatic function, as impairment can prolong insulin action and increase hypoglycemia risk.
• Adjust doses during periods of illness, reduced food intake, or increased physical activity.
• Monitor blood glucose closely during pregnancy; insulin requirements may change rapidly.
• Avoid use in patients with known hypersensitivity to human insulin or any excipients in the formulation.
• Educate patients on proper injection technique and rotation of sites to prevent lipohypertrophy.
• Review concomitant medications that may mask hypoglycemia symptoms, such as beta‑blockers.

Humulin 30/70 can interact with other drugs, affecting glucose control or insulin pharmacodynamics.

Avoid

• Concurrent use of other rapid‑acting insulins or concentrated insulin formulations without dose adjustment.
• MAO‑B inhibitors that may potentiate hypoglycemic episodes.

Use with caution

• Beta‑blockers, which can blunt hypoglycemia warning signs.
• Thiazide diuretics and corticosteroids, which may raise blood glucose and require insulin dose increases.
• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk when combined with premixed insulin.
• Alcohol, especially in excess, because it can cause delayed hypoglycemia.